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The addition of chemotherapeutic agents to radiation has con-
tributed to improve clinical outcomes in most patients with
solid tumours and is representing, nowadays, the standard of
treatment.
1. Why? Rational for the concurrent use of
radiotherapy and chemotherapy
Spatial cooperation mechanism describes how radiation
treats the primary location while chemotherapy is added to
deal with systemic spread. In this approach, the effectiveness
of the chemotherapeutic agent is critical in the success of the
combined treatment and is well know that in common solid
tumours chemotherapy can seldom achieve a survival fraction
lower than 10−6. As spatial cooperation is, indeed, targeting
different anatomical sites and full doses of chemotherapy and
radiotherapy are required, the optimal combination of both
modalities of treatment is sequential.1
Citotoxic enhancement explained how the capacity of
chemotherapy to modify the cell response to radiotherapy
can provide a greater effect on cell survival than it would
be expected from the mere additivity of their independent
effects. That benefit relies commonly on increasing in the ini-
tial DNA damage caused by radiation, interfering in the cell
capability of repairing DNA damage, temporally modulating
the cell cycle. Despite that fact, toxicity caused by radiation is
expressed locally while drugs cause mainly systemic toxicity,
even when local toxicity can be increased by their simulta-
neous use. Concurrent use of chemotherapy and radiotherapy
is mandatory if this citotoxic enhancement is aimed to be
obtained.1
2. What? Main chemotherapeutic agents
use concurrently with radiotherapy
2.1. Platinum compounds
Cisplatin and its analogues, increase the effect of radiation
through the formation of toxic platinum intermediates in the
presence of free radicals, the fixation by cisplatin of other-
wise reparable DNA damage primarily caused by radiation, the
increase of cisplatin cellular uptake after radiation, a synergis-
tic disruption in cell cycle and the inhibition of DNA damage
repair.2
2.2. Fluoropyrimidines
5-Fluoruracil (5-FU) and its prodrugs have shown S-phase spe-
cific toxicity, a phase in the cycle when the cell is particularly
resistant to radiation induced damage.3 Protracted infusion is
required to achieve optimal radiosensitization, thereby a sta-
ble concentration of an orally given prodrug as capecitabine
can provide the same results and, indeed, is replacing pro-
tracted infusion of 5-FU in some indications.
2.3. Gemcitabine
Gemcitabine produces an increase in radiosensitivity even
at nontoxic concentrations. The interference with DNA
synthesis and repair mechanism caused by the depletion
of phosphorylated deoxynucleotides through the inhibition
of ribonucleotide reductase has been claimed to be the
1507-1367/$ – see front matter © 2013 Published by Elsevier Urban & Partner Sp. z o.o. on behalf of Greater Poland Cancer Centre.
http://dx.doi.org/10.1016/j.rpor.2013.04.001
S8 reports of practical oncology and radiotherapy 1 8 ( 2 0 1 3 ) S7–S8
underlying mechanism of enhancement.4 Moreover, that
depletion is leading to cell accumulation in S-phase, so cell
cycle redistribution must be simultaneous with deoxyadeno-
sine triphosphate pool depletion.
3. For whom? Main clinical indications of
concurrent chemoradiation
The role of chemoradiation in the treatment of locoregional
disease is preponderant, gaining new indications onward the
basis of solid scientific evidence.
Head and neck squamous cell carcinoma is, probably,
the best-studied indication. Meta-analysis have shown a sig-
nificant benefit in survival (OS 5 years benefit: 8%) when
chemotherapy is given concurrently with radiation, being
the benefit higher in patients receiving platinum-based
chemotherapy.5,6
A risk of death reduction of 14% has been shown in non
small-cell lung carcinoma for the concurrent treatment when
compared with radiotherapy alone, but oesophagitis, anaemia
and neutropenia are also significantly increased.7
In limited stage small cell carcinoma, concurrent chemora-
diation improved overall survival but the optimal combination
and timing is conflicting.8
An absolute overall survival improvement by 10% has been
shown by the addition of chemotherapy, mainly cisplatin,
to radiation in cancer of the uterine cervix, with a parallel
increase in haematological and gastrointestinal toxicity.9 The
benefit of induction chemotherapy has also been explored.
Despite a trend to survival benefit in those schemes contain-
ing cisplatin doses over 25 mg/m2, all other settings showed a
detrimental effect on survival.10
Strong evidence supports the use of concurrent chemora-
diation in gastrointestinal malignacies such as oesophageal
cancer, gastric cancer, rectal adenocarcinoma and anal canal
squamous carcinoma, as a preoperative, adjuvant or salvage
treatment, depending on the disease.
4. Conclusions
Chemotherapy when applied concurrently with radiation has
singular biological mechanisms and specific toxicity profile,
that fact makes the difference between this concurrent set-
ting and its use as a single agent. Radiation oncologists
have to be proficient in its use and the specific knowledge
necessary to manage concurrent chemoradiation schemes
must be a comprehensive part of their training as it is recorded
in the European Core Curriculum for Radiation Oncologists’
training.11
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